Skip to main content

Table 1 Patient characteristics

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Characteristic %
Age (years)
 Median63 
 Range37–77 
Sex
 Male7572.1
 Female2927.9
ECOG PS
 09389.4
 1109.6
 211
Location of pancreatic tumor
 Head2726
 Body/tail4644.2
 Recurrent after resection3129.8
Metastatic site
 Liver7269.2
 Lung1918.3
 Peritoneum1615.4
Biliary drainage
 Yes1817.3
 No8682.7
UGT1A1*6/UGT1A1*28
 Wild/wild4846.2
 Wild/heterozygous1312.5
 Heterozygous/wild3331.7
 Heterozygous/heterozygous43.8
 Homozygous (*6 or *28)43.8
 NA21.9
CEA (ng/mL)
 Median6.1 
 Range1.2–10,068 
CA19–9 (IU/mL)
 Median814.5 
 Range2–50,000 
Alb (g/dL)
 Median3.6 
 Range2.5–4.4 
CRP (mg/dL)
 Median0.31 
 Range0.01–8.75 
  1. Alb albumin, CA19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, NA not available, UGT1A1 uridine diphosphate glucuronosyltransferase 1A1